Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors

In conclusion, novel therapeutic perspectives are emerging for CML, holding the potential for substantial advancements in disease treatment.PMID:38488824 | DOI:10.1080/14656566.2024.2331778

Source: Expert Opinion on Pharmacotherapy - March 15, 2024 Category: Drugs & Pharmacology Authors: Alessandro Costa Emilia Scalzulli Ida Carmosino Claudia Ielo Maria Laura Bisegna Maurizio Martelli Massimo Breccia Source Type: research